(Q36425154)

14 August 2017

1 reference

title

Efficacy of systemic therapy in advanced pancreatic carcinoma (English)

1 reference

14 August 2017

1 reference

Anders Lideståhl

1

1 reference

14 August 2017

Johan Permert

2

1 reference

14 August 2017

Stefan Linder

3

1 reference

14 August 2017

Håkan Bylund

4

1 reference

14 August 2017

Nick Edsborg

5

1 reference

14 August 2017

Pehr Lind

6

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

45

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

136-143

1 reference

Cancer burden in the year 2000. The global picture

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Resection for pancreatic cancer in the new millennium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

A systematic overview of chemotherapy effects in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Phase II study of gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

Virulizin(R) - A review of its antineoplastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860500537861

10.1080/02841860500537861

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference